Ruxolitinib (Jakafi, Jakafi XR and Jakavi)

Medicine at a glance

Ruxolitinib is a targeted treatment that blocks proteins called Janus kinases, usually shortened to JAKs. It can help control abnormal blood-cell signalling and inflammation. Your specialist will explain the purpose of treatment in your situation and what improvement they hope to see. Regular blood tests and infection precautions are important even when you feel well.

Check the exact product on your prescription. Conventional Jakafi and Jakavi tablets are usually taken twice daily. Jakafi XR is an extended-release tablet with a usual once-daily schedule. The current European Jakavi information also includes an oral solution. Different formulations have different strengths and instructions; changing between them requires a new, checked prescription.

This article concerns oral treatment. Opzelura contains ruxolitinib in a skin cream. It is not an alternative to the oral medicine, and instructions for the cream must not be applied to tablets or liquid.

What ruxolitinib is and how it works

JAK1 and JAK2 are proteins that carry messages inside cells. These messages help regulate blood-cell production and immune responses. Ruxolitinib reduces activity in these pathways. Depending on the treatment setting, this may help with an enlarged spleen, troublesome disease symptoms, abnormal blood production or harmful inflammation. It also affects normal immune and blood-forming cells, which explains several important side effects.

This is a targeted kinase inhibitor, not conventional chemotherapy or an immune-checkpoint antibody. Its immune-suppressing effects also explain its use in specialist care after a donor stem-cell transplant. Graft-versus-host disease, or GvHD, means donor immune cells are attacking the recipient's tissues. That setting has its own dosing, accompanying medicines and infection risks.

Treatment is not a promise of cure. Feeling better does not make monitoring unnecessary, and side effects do not prove that treatment is working. Your team looks at symptoms, examination findings and blood results together.

How the team decides whether it is suitable

The specialist considers your diagnosis, previous treatment, blood counts, spleen and symptom assessments, other illnesses and current medicines. Genetic tests may help establish the diagnosis or explain the disease. However, ruxolitinib does not have a universal requirement for a positive JAK2 mutation test. Do not assume that a negative result automatically rules it out.

Platelet counts are particularly important because platelets help blood clot, and treatment can lower them further. Haemoglobin and white-cell counts also influence the prescription. Kidney or liver impairment can change the dose or make particular schedules unsuitable. US and European adjustment rules differ; dialysis needs a specific plan, with US doses scheduled after dialysis rather than before it.

Children require specialist assessment. The US and European age limits for post-transplant treatment differ, and the European oral solution supports age- or body-size-based prescriptions. These are not simply smaller versions of an adult cancer prescription. Treatment for myelofibrosis or polycythaemia vera is not established in children in the reviewed US information.

Before treatment starts

Expect a full blood count, including different types of white cells, and assessment of liver and kidney function. The team reviews your infection history and may arrange other tests according to your condition. Tell them about previous tuberculosis, close contact with someone with tuberculosis, hepatitis B, shingles, recurrent cold sores or unusual infections. European information recommends hepatitis B screening before treatment; tuberculosis assessment follows risk and local recommendations.

An active serious infection should be treated and resolved before starting. A previous infection does not always prevent treatment, but may require specialist advice, preventive medicine and extra monitoring. Tell the team if you already take an antiviral, antibiotic or antifungal: some of these medicines change ruxolitinib levels.

Discuss previous skin cancer, new skin lesions, smoking history, blood clots, heart disease, stroke and diabetes. Bring a complete medicine list, including supplements and remedies bought without a prescription. Ask about vaccination timing, pregnancy prevention and fertility before the first dose.

Before leaving, understand your tablet or liquid strength, the number of doses each day, the next blood-test date and the hospital's urgent contact route. Arrange repeat supplies early: running out can cause an unplanned interruption.

How to take ruxolitinib

Your own dose and calendar

Conventional tablets are generally taken morning and evening; Jakafi XR is usually taken once daily. Both can be taken with or without food. Use consistent times and follow the latest dispensing label. Treatment commonly continues every day without planned weekly breaks, although your specialist may deliberately reduce, pause or stop it.

There is no single starting dose for everyone. For example, in one adult myelofibrosis schedule, a platelet count above 200 × 10⁹/L corresponds to conventional Jakafi 20 mg twice daily or Jakafi XR 44 mg once daily. Lower platelet counts require lower starting doses, and other treatment settings use different schedules. These examples demonstrate why the milligram numbers are not interchangeable; they are not instructions to select or convert your dose yourself.

Check every new pack, especially after a dose change. Ask the pharmacist to update your written schedule and explain what to do with older strengths. Never combine old and new prescriptions to use up tablets.

Swallowing, liquid and feeding tubes

Swallow tablets with water. Do not crush, chew or break them yourself. In particular, Jakafi XR must remain whole because damaging it changes the extended-release formulation. Contact the pharmacy before the next dose if swallowing becomes difficult.

The European Jakavi oral solution contains 5 mg in each mL. Use the supplied oral syringe and the prescribed volume, not a kitchen spoon. Shake the bottle before opening, follow the leaflet's measuring instructions and drink water afterwards if advised to help swallow the whole dose. Have the pharmacist demonstrate the method. Wash hands before measuring, use a new supplied syringe with each new bottle and wash any solution off skin with soap and water. The solution contains propylene glycol and preservatives, which require particular consideration in young children and when other medicines contain similar ingredients.

A labelled nasogastric-tube method exists for conventional US Jakafi tablets. It requires a specified tube size, preparation, timing and flushing procedure supervised by the clinical team. It does not authorise putting Jakafi XR through a tube or making a home liquid from any ruxolitinib product. European Jakavi oral solution also has its own labelled nasogastric or gastric feeding-tube instructions. Ask the team to use the instructions for that exact formulation. Tube feeds and fluid restrictions also need pharmacy review.

Missed doses, vomiting and storage

If a dose is missed, skip it and take the next usual prescribed dose. Do not take an extra or double dose. After vomiting a conventional tablet, do not replace it; take the next dose when due. For XR or the oral solution, obtain a formulation-specific vomiting plan rather than guessing how much was absorbed; do not take a replacement without advice. Repeated vomiting or inability to retain treatment needs prompt contact because prolonged interruption can matter.

If you take too much, contact the team or emergency department immediately, bringing the pack and dose details. Store treatment securely away from children. US tablets require controlled room temperature and protection from light; European tablets and solution should not be stored above 30°C (86°F). Write the opening date on Jakavi liquid and use it within 60 days. Follow your own pack's conditions and return unwanted medicine to the pharmacy.

Monitoring and checking whether treatment is working

Blood counts are checked before treatment and commonly every two to four weeks until the dose is stable, then as clinically needed. More frequent testing may be necessary with low counts, interacting medicines, organ impairment or post-transplant complications. Tests help the team act before symptoms become severe.

Liver and kidney tests, blood pressure and other measurements follow your treatment plan. Cholesterol and triglycerides, which are fats in the blood, can rise. The US label recommends a lipid check approximately eight to twelve weeks after starting; European information also recommends lipid monitoring and treatment when needed. Periodic skin examinations are important.

Response assessment may include blood-count control, spleen size, appetite, weight, night sweats, itching, fatigue and daily function. Transplant teams also assess the organs affected by GvHD. Recording changes between appointments can make these discussions more useful.

Dose reduction or a supervised pause can be part of safe treatment. Ask who will tell you when to restart and at what dose. Do not interpret a blood result or restart leftover tablets independently.

Common side effects and practical management

Low blood counts and bruising

Anaemia means too few red blood cells or too little haemoglobin to carry oxygen effectively. You may feel more tired, pale, dizzy or breathless. Report a change rather than assuming it is ordinary fatigue. The team may adjust treatment or arrange a transfusion. Severe breathlessness, chest pain or fainting needs emergency assessment.

Low platelets can cause bruising, nosebleeds, bleeding gums or small red or purple skin spots. Use a soft toothbrush and avoid activities likely to cause injury when counts are low. Report new bleeding. Major bleeding, black stools, vomiting blood or a severe headache with neurological symptoms needs emergency care. Do not add aspirin or anti-inflammatory painkillers without advice; prescribed aspirin may be part of your blood-condition treatment and should not be stopped independently.

Tiredness, dizziness and headache

Plan demanding tasks for times when you have more energy, rest when needed and keep gently active if safe. Dizziness may relate to treatment, anaemia, dehydration or another problem. Rise slowly and avoid driving while affected. Tell the team about persistent headache; sudden severe headache or new weakness needs urgent assessment.

Digestive symptoms and weight changes

Nausea, diarrhoea, constipation or abdominal discomfort can occur, with patterns differing between treatment settings. Small meals, prescribed anti-sickness medicine and regular fluids may help. Follow any fluid restriction. Report persistent diarrhoea or vomiting, inability to drink, reduced urine, blood in stool or severe abdominal pain. Do not assume all diarrhoea is a routine drug effect, particularly after transplantation.

Weight can increase, sometimes alongside improved appetite, but unexplained rapid gain or swelling should be reported. Ask for dietary support if weight changes are troublesome. Complete hair loss is not a characteristic common effect in the reviewed oral-treatment information; report any hair or skin changes so other causes can be assessed.

Changes found on blood tests

Cholesterol, liver enzymes and other laboratory values may change without symptoms. Keep tests even if daily life feels normal. Yellow skin or eyes, dark urine, marked nausea or right-sided upper abdominal pain warrants prompt assessment.

Important risks that need medical assessment

Serious infections and viral reactivation

Ruxolitinib can weaken infection defences, with or without a very low white-cell count. Serious bacterial, fungal, viral and tuberculosis infections have occurred. Fever, chills, new cough, painful urination or suddenly feeling very unwell needs urgent advice. Infection can be serious even without a high temperature.

Old infections can become active again. A painful, tingling, blistering patch may be shingles; report it promptly, especially near an eye. Herpes simplex can reactivate and spread more widely; the frequency of these postmarketing reports is uncertain. Report worsening cold sores, genital sores or widespread blisters. Hepatitis B may reactivate, requiring blood monitoring and antiviral management. Preventive medicines are individualised; do not stop them when you start feeling better.

New neurological symptoms

A rare serious brain infection called progressive multifocal leukoencephalopathy, or PML, has been reported. New changes in memory, personality, vision, speech, balance or limb strength need urgent assessment; family members may notice first. Sudden symptoms could also be a stroke and require emergency care. If PML is suspected, the team must stop further dosing while investigating.

Problems during a treatment interruption

Disease symptoms can return after stopping, sometimes within about a week. Some patients have developed a severe inflammatory deterioration with fever, breathing difficulty, low blood pressure, abnormal clotting or organ failure. This can happen during dose reduction as well as after stopping. Do not arrange your own drug holiday.

If treatment must end, the team may reduce it gradually. Life-threatening toxicity can require immediate stopping instead. New illness during a taper or interruption must be assessed promptly; severe breathlessness, collapse or confusion is an emergency. Never restart or increase the dose yourself to treat a suspected withdrawal reaction.

Skin cancer, cardiovascular problems and clots

Certain skin cancers have occurred during treatment. Report a changing mole, persistent sore or new skin lump. Protect skin from strong sunlight and attend skin examinations. Tell the team about any previous cancer.

Labels also contain cautions about major heart events, clots and additional cancers. Some evidence comes from another JAK inhibitor used for rheumatoid arthritis, and those risk estimates cannot simply be transferred to ruxolitinib. Nevertheless, smoking, age and cardiovascular history affect the discussion. Chest pain, stroke symptoms or sudden breathlessness needs emergency care; a newly swollen painful limb needs urgent assessment.

Low blood sugar

Current US information includes postmarketing reports of hypoglycaemia, meaning low blood sugar, as a JAK-inhibitor class effect. Frequency cannot be reliably estimated from these reports. Tell the team if you have diabetes and ask whether glucose checks need adjustment. If sweating, shaking, unusual hunger or confusion occurs, check glucose promptly if possible and follow your agreed diabetes treatment plan. Contact the team if you have these symptoms without a plan or they do not resolve. A seizure, collapse or reduced consciousness is an emergency; never give food or drink to someone who is unconscious.

Other medicines, supplements and vaccinations

Ruxolitinib levels can change when other medicines affect liver enzymes, especially CYP3A4 and CYP2C9. Relevant examples include some antifungals, antibiotics, antiviral treatments, epilepsy medicines, rifampicin and St John's wort. Avoid grapefruit and grapefruit juice. Have every new prescription and non-prescription product checked.

Fluconazole needs particular attention: both US and European instructions advise avoiding doses above 200 mg daily with ruxolitinib. Lower doses may require ruxolitinib reduction. Rules for other strong enzyme inhibitors differ by treatment setting and region; some US GvHD situations use closer blood-count monitoring instead of an automatic reduction. Do not halve your own dose or stop an essential anti-infective.

European information also advises monitoring certain transporter-sensitive medicines, including dabigatran, ciclosporin, rosuvastatin and potentially digoxin. Do not change their timing without a pharmacy plan. Blood thinners, aspirin and anti-inflammatory painkillers need a bleeding-risk review. Diabetes medicines may also need review if glucose falls. Supplements described as natural are not automatically safe.

Discuss vaccinations with the treating team, particularly live vaccines. Vaccine choice, timing and expected response depend on immune suppression, blood counts and transplant history. Preventive antivirals or antibiotics do not remove the need to report symptoms.

Everyday life during treatment

Use reminders and keep an up-to-date dose list. Travel plans should include enough medicine, monitoring arrangements, safe storage and access to urgent care. Contact the team early if a delayed delivery might leave you without treatment.

Wash hands regularly, use sensible food hygiene and avoid close contact with people who are unwell. Balance these precautions with safe activity and social support. Discuss alcohol, especially with liver problems. Do not drive, cycle in traffic or operate machinery when dizzy or less alert.

Tell dentists and other clinicians you take ruxolitinib. Procedures may need blood-count checks and an agreed medicine plan, but there is no universal self-directed pre-operative stopping interval. Work adjustments, rest breaks and help with travel to blood tests may make treatment easier to manage. Discuss sexual discomfort, anxiety or persistent fatigue with the team.

Fertility, contraception, pregnancy and breastfeeding

Discuss pregnancy plans before starting. Animal findings raise concern about harm to an unborn baby, while human pregnancy evidence is limited. European Jakavi information contraindicates use during pregnancy and requires effective contraception during treatment. If pregnancy occurs or is suspected, contact the specialist promptly for an individual plan; do not stop abruptly without that discussion.

The reviewed oral labels do not supply one universal post-treatment contraception interval or a fixed partner interval to apply to everyone. Ask for written advice covering your formulation, other medicines and both partners' circumstances. Do not borrow a precaution period from another JAK inhibitor or from the skin cream.

Do not breastfeed during oral treatment. The US label also specifies two weeks after the last dose. European information does not give the same fixed interval afterwards, so agree a safe restart date rather than assuming breastfeeding can resume immediately.

Human fertility effects are uncertain. If preserving fertility matters to you, discuss options before treatment, taking previous chemotherapy or transplantation into account. Contraception is still needed even if fertility is thought to be reduced.

After treatment finishes

Stopping needs a written plan. Keep any taper appointments and blood tests, and know which symptoms require urgent contact. The taper for a post-transplant problem can differ substantially from a plan for a blood cancer; there is no single schedule for everyone.

Continue agreed infection prevention, reproductive precautions and follow-up. Report fever, new breathing problems, marked weakness or confusion after the final dose. Your team will assess whether symptoms reflect infection, returning disease or an interruption-related reaction. Return unused treatment safely; do not restart an old pack yourself.

Frequently asked questions